UroGen Pharma is valued at around $1.21 billion and rated as a 'Buy' due to its potential 65% growth by 2027. The company has two approved products, Jelmyto and Zusdori, using its proprietary RT Gel delivery system. While Jelmyto's sales have been disappointing, Zusdori is expected to drive significant future growth. UroGen also maintains a strong financial position with $90 million in cash and marketable securities, plus $121 million in receivables, reducing near-term financial risks.
UroGen Pharma is the subject of this update, with Pluang's health sector market snapshot as of Nov 09, 2026 19:41 WIB showing that out of 150 priced US health stocks, 121 rose and 18 fell today. Notable movers include NUWE at USD 4.72 with a 3.06% increase, CTXR at USD 0.54 with a 2.98% decrease, and LQDA at USD 45.67 with a 2.86% increase. The most notable figure is the strong breadth of 121 rising stocks.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
